AtonRa Partners’s Emergent Biosolutions EBS Stock Holding History

AtonRa Partners’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-11,505	Closed	-$472K	–	131
2022 Q1	$472K	Sell	11,505 -2,473	-18%	-$109K	0.26%	106
2021 Q4	$608K	Sell	13,978 -541	-4%	-$24.5K	0.21%	107
2021 Q3	$727K	Buy	14,519 +405	+3%	+$24.5K	0.24%	109
2021 Q2	$889K	Sell	14,114 -1,361	-9%	-$87.4K	0.33%	103
2021 Q1	$1.44M	Buy	15,475 +3,355	+28%	+$344K	0.64%	62
2020 Q4	$1.09M	Buy	+12,120	New	+$1.11M	0.53%	61

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AtonRa Partners's EBS Position: Q2 2022 in Review

AtonRa Partners sold out of Emergent Biosolutions (EBS) in Q2 2022, closing a stake of 11,505 shares — an estimated $472K sold.

AtonRa Partners first reported a position in EBS in Q4 2020 and held it in 6 quarters. The position peaked at $1.44M in Q1 2021. 232 funds tracked by Wall St. Rank hold EBS as of Q2 2022.

AtonRa Partners reported no remaining Emergent Biosolutions position as of Q2 2022 after selling out during the quarter.
AtonRa Partners sold 11,505 Emergent Biosolutions shares in Q2 2022, an estimated $472K.
AtonRa Partners first reported a position in Emergent Biosolutions in Q4 2020 and held it in 6 quarters.
AtonRa Partners's Emergent Biosolutions position peaked at $1.44M in Q1 2021.
232 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2022.

Based on AtonRa Partners's 13F filing for Q2 2022, filed 15 Aug 2022.